Saby George

8PUBLICATIONS
55CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsHaematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jan 06, 2025
Treatment Patterns and Costs Among Patients With Metastatic Renal Cell Carcinoma in the United States: A Real-World Study Using Integrated Claims and Clinical Data.

Daniel M Geynisman, Nathan R Hill, Lisa C Rosenblatt

|Aug 26, 2024
TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy.

Daniel P Petrylak, Scott T Tagawa, Rohit K Jain

|Oct 20, 2023
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma.

Daniel P Petrylak, Bernhard J Eigl, Saby George

|Jun 27, 2023
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.

Peter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak

|May 06, 2021
The Impact of Adverse Events on Health Care Resource Utilization, Costs, and Mortality Among Patients Treated with Immune Checkpoint Inhibitors.

Saby George, Elizabeth J Bell, Ying Zheng

|Sep 03, 2020
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma.

Nizar M Tannir, Sabina Signoretti, Toni K Choueiri

Pageof 2

Frequent Collaborators

3 joint publications

Daniel P Petrylak

2 joint publications

Neeraj Agarwal

2 joint publications

Daniel M Geynisman

2 joint publications

Chethan Ramamurthy